Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-25-013763
Filing Date
2025-02-04
Accepted
2025-02-04 17:31:30
Documents
1
Period of Report
2025-01-31

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 7518
  Complete submission text file 0000950170-25-013763.txt   9088
Mailing Address C/O INTRA-CELLULAR THERAPIES, INC. 135 ROUTE 202/206 BEDMINSTER NJ 07921
Business Address
Halstead Michael (Reporting) CIK: 0001521548 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36274 | Film No.: 25589776

Mailing Address 135 ROUTE 202/206 SUITE 6 BEDMINSTER NJ 07921
Business Address 135 ROUTE 202/206 SUITE 6 BEDMINSTER NJ 07921 (646) 440-9333
Intra-Cellular Therapies, Inc. (Issuer) CIK: 0001567514 (see all company filings)

EIN.: 364742850 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)